ACADIA Pharmaceuticals Inc (ACAD)vsargenx NV ADR (ARGX)
ACAD
ACADIA Pharmaceuticals Inc
$22.01
+5.01%
HEALTHCARE · Cap: $3.57B
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 295% more annual revenue ($4.24B vs $1.07B). ACAD leads profitability with a 36.5% profit margin vs 30.5%. ARGX appears more attractively valued with a PEG of 0.83. ACAD earns a higher WallStSmart Score of 66/100 (B-).
ACAD
Strong Buy66
out of 100
Grade: B-
ARGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+79.1%
Fair Value
$107.64
Current Price
$22.01
$85.63 discount
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 40 in profit
Keeps 37 of every $100 in revenue as profit
Earnings expanding 86.2% YoY
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ACAD
The strongest argument for ACAD centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 36.5% and operating margin at 6.1%.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bear Case : ACAD
The primary concerns for ACAD are Piotroski F-Score, PEG Ratio, Free Cash Flow.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ACAD profiles as a mature stock while ARGX is a growth play — different risk/reward profiles.
ACAD carries more volatility with a beta of 0.81 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ACAD scores higher overall (66/100 vs 63/100), backed by strong 36.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ACADIA Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?